

Review Article

Genetic modeling of ovarian phenotypes in mice for the study of human polycystic ovary syndrome

Yi Feng^{1,2}, Xin Li³, Ruijin Shao¹

¹Department of Physiology/Endocrinology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; ²Department of Integrative Medicine and Neurobiology, State Key Laboratory of Medical Neurobiology, Shanghai Medical College; Institute of Acupuncture Research (WHO Collaborating Center for Traditional Medicine); Institutes of Brain Science, Fudan University, Shanghai, China; ³Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, China

Received November 28, 2012; Accepted December 29, 2012; Epub January 21, 2013; Published January 30, 2013

Abstract: Polycystic ovary syndrome (PCOS) presents with a range of clinical complications including hyperandrogenism, polycystic ovaries, chronic oligo/anovulation, infertility, and metabolic alterations related to insulin resistance. Because the mechanism by which this disorder develops is poorly understood, information from experimental models of human disease phenotypes may help to define the mechanisms for the initiation and development of PCOS-related pathological events. The establishment of animal models compatible with human PCOS is challenging, and applying the lessons learned from these models to human PCOS is often complicated. In this mini-review we provide examples of currently available genetic mouse models, their ovarian phenotypes, and their possible relationship to different aspects of human PCOS. Because of the practical and ethical limitations of studying PCOS-related events in humans, our understanding of the mechanisms that contribute to the etiology of human PCOS may be enhanced through further study of these transgenic and knockout mouse models.

Keywords: PCOS, hemorrhagic cystic follicles, transgenic and knockout mice

Introduction

Polycystic ovary syndrome (PCOS), a complex genetic disorder, is a significant women's health issue due to its high incidence and the fact that it often occurs before puberty [1]. It is estimated to affect 8–17% of women of reproductive age worldwide, and the number of reported cases of human PCOS increases annually [2]. The disorder presents with a wide range of clinical complications including hyperandrogenism, polycystic ovaries, chronic oligo/anovulation, infertility, hyperinsulinemia, insulin resistance, and a higher prevalence of obesity [3]. The etiology of the disease and the mechanisms by which this disorder progresses are still unclear, and this makes understanding the pathophysiology of human PCOS challenging. Although abnormal gene expression profiles in the ovaries and theca cells of women with PCOS have been identified [4, 5], transgenic and knockout (KO) mouse models with pathological ovarian

phenotypes mimicking those found in human PCOS are still of great interest. The value of developing such animal models is in their providing a means to systematically analyze the mechanisms underlying the development of PCOS. These models can also provide new insights into the etiology of PCOS and provide opportunities to explore diverse aspects of the disease such as drug development.

A polycystic ovary morphology is consistent with, but not essential for, the diagnosis of human PCOS [3]. Pathological ovarian features include arrest of follicular development, accumulation of multiple follicular cysts, and an increase in ovarian stromal thickness. These features lead to chronic oligo- or anovulation and subsequent infertility [3, 6].

Autocrine, paracrine, and endocrine factors are necessary for normal ovarian function in mammals [6], and proper ovarian function is depen-

dent upon several specialized cell lineages in a spatially ordered configuration. It is expected, therefore, that many genes are required to orchestrate ovarian cellular function and that intercellular signaling events will participate in the development of PCOS. However, the cellular and molecular mechanisms underlying the development of cystic and/or hemorrhagic follicles containing an enlarged theca cell layer are not well defined. This review briefly describes several transgenic and KO mouse models of human PCOS (**Table 1**), and discusses their ovarian phenotypes and the advantages and possible limitations of applying these models to human PCOS.

Genetic modeling of ovarian phenotypes in mice

Several lines of evidence indicate that changes in the production of luteinizing hormone (LH) in the pituitary gland are important for the development of cystic follicles in human PCOS. For example, women suffering from PCOS exhibit significantly increased levels of circulating LH compared to healthy controls [7]. Ovarian theca cells are the cell type that predominately expresses the LH receptor [8], and these cells become hypersensitive to LH during the development of human PCOS [1, 9]. Furthermore, chronic treatment with human chorionic gonadotropin (hCG) [10] or overexpression of LH and hCG [11-13] in female mice induces cystic follicle formation in the ovary. However, development of cystic or hemorrhagic follicles does not always occur along with an increase in LH levels in female mice that overexpress hCG under the control of different promoters [14, 15]. Although female follicle-stimulating hormone (FSH) β knockout mice have been shown to have increased levels of circulating LH, there is no evidence for the development of cystic or hemorrhagic follicles in FSH-deficient female mice [16]. In addition, overexpression of FSH β leads to detectable numbers of cystic or hemorrhagic follicles without changes to circulating LH levels [17]. Thus, although LH is essential for the later stages of follicular development (from preovulatory to periovulatory stages) and ovulation, these results argue in favor of a primary role for LH in the formation of cystic or hemorrhagic follicles in the ovary.

It is generally accepted that elevated androgens are the main culprit behind the develop-

ment of PCOS [1]. It is notable, however, that polycystic ovaries exist in women during pubertal development [18] and in women with hyperandrogenism [1] even when LH secretion and pulsatility is normal [19]. It has been shown that long-term treatment with estradiol valerate (EV) or dihydrotestosterone causes the formation of polycystic ovaries in rats [20-23]. Furthermore, treatment with letrozole, an aromatase cytochrome P450 (P450arom) blocker, inhibits androgen-to-estrogen conversion and leads to the development of massive multiple follicular cysts in rats [23]. Thus, both clinical and experimental studies suggest that a dynamic equilibrium among ovarian steroid hormones plays a significant role in the development of multiple cystic follicles under both physiological and pathological conditions.

Animal studies have demonstrated that both estrogens and androgens contribute to folliculogenesis, ovarian remodeling, and the development of several diseases [24]. There is *in vivo* and *in vitro* evidence to support the idea that the proliferation of theca cells in growing follicles results in significant androgen biosynthesis [1], but estrogens have been shown to inhibit androgen production in estrogen receptor (ER) α -expressing theca cells [25-27]. The absence of P450arom in theca cells is reflective of the paracrine action of ovarian-derived estrogens in the activation of ER α signaling *in vivo* [28, 29]. Understanding the role of ER α in the regulation of theca cell function has been aided by the global and theca cell-specific deletion of the ER α and/or ER β gene in mice [30-34]. The initial analyses of the ovaries of these KO mice indicate that formation of hemorrhagic cystic follicles is likely to arise from the loss of ovarian ER α action in theca cells. Similarly to the ER α KO mice (ER α KO) [30-34], female mice overexpressing LH/hCG [11-13] or lacking plasminogen activator inhibitor-1 (PAI-1) [35] also exhibited theca cell hyperplasia that is consistent with that seen in human PCOS [36]. However, although female mice lacking P450arom (ArKO mice) developed hemorrhagic cystic follicles [28, 29], histological examination showed no hyperplasia of the theca cells in the ArKO ovaries. These studies lead to at least two conclusions: (1) there is no cause-and-effect relationship between theca cell hyperplasia and the formation of cystic and hemorrhagic follicles, and (2) altered estrogen

Polycystic ovary-like mouse models

Table 1. Published mouse models that have ovarian alterations and their accompanying PCOS-like phenotypes

Transgenic or knockout models	Ovarian phenotype			Ovulation	Infertility	Anterior pituitary		Sex steroids				Reference
	Follicular cysts	Hemorrhagic cysts	TC / IC			FSH	LH/hCG	E2	P4	T/DHT	A	
1. Overexpression of hCG α β	+	+, massive	hyperplasia	No	Yes	n.d.	↑	↑	n.d.	n.d.	n.d.	[11]
2. Overexpression of bovine LH β	+, large	+, frequent	hyperplasia	No	Yes	n.d.	↑	↑	↑	↑	n.d.	[12, 13]
3. ER α BKO	+	+	n.d.	No	Yes	-	↑	-	n.d.	↑	-	[30, 32]
4. ER α KO	+, large	+, frequent	hyperplasia	No	Yes	-	↑	↑	-	↑	↑	[30-32, 34, 37]
5. TC-specific ER α KO with PMSG/hCG stimulation	+, large	+, frequent	hyperplasia	Yes (oocytes ↓)	Age-dependent	-	↓	n.d.	n.d.	↑	n.d.	[31]
6. Overexpression of NGF	No	No	n.d.	Yes	No	-	-	-	↑	-	-	[40]
7. Overexpression of NGF with PMSG/hCG stimulation	+, large	+, frequent	n.d.	Yes (pups ↓)	n.d.	n.d.	n.d.	↑	↓	↑	-	[40]
8. Overexpression of hPAI-1	+, large	+	hyperplasia	No	n.d.	n.d.	n.d.	-	-	↑	n.d.	[35]

TC, theca cells; IC, interstitial cells; FSH, follicle-stimulating hormone; LH, luteinizing hormone; E2, 17 β -estradiol; P4, progesterone; T, testosterone; A, androstene/androstenedione; PMSG, pregnant mare's serum gonadotropin; hCG, human chorionic gonadotropin; ER, estrogen receptor; NGF, nerve growth factor; hPAI-1, human plasminogen activator inhibitor-1; +, presence; -, no changes vs. wild-type controls; ↑, increased vs. wild-type controls; ↓, decreased vs. wild-type controls; n.d., not determined.

biosynthesis in P450arom-expressing granulosa cells or the estrogenic action on ER α -expressing theca cells is likely involved in the formation of cystic and hemorrhagic follicles.

Because human PCOS is often associated with metabolic disturbances [3, 18], caution should be taken when selecting the appropriate transgenic or KO models based solely on their ovarian phenotype. In addition to impaired ovarian function and fertility, the onset of insulin resistance and diabetes observed in adult female ER α KO mice [37] mimics what is seen in some PCOS patients [1, 18]. Thus, activation of ER α may serve as a critical link between reproduction and metabolic disturbances. Although it remains to be determined what effects theca cell-specific deletion of ER α has on metabolism, the ER α KO mouse model can be useful for progressive studies of ovarian dysfunction and metabolic changes or for expanded studies that seek to understand the complex PCOS signature.

Manipulation of endogenous estrogen levels by treatment with EV or gonadotropin from pregnant mare serum has previously been shown to increase the production of ovarian nerve growth factor (NGF) in rat theca cells and to induce the formation of follicular cysts [38, 39]. Moreover, intraovarian treatment with a neutralizing anti-serum to NGF in conjunction with systemic

exposure to an antisense oligodeoxynucleotide to the p75 NGF receptor reduces the number of precystic and cystic follicles [39]. This demonstrates that it is possible to prevent the development of cystic follicles by inhibiting NGF signaling. Transgenic NGF female mice, however, are indistinguishable from wild-type animals in all major reproductive functions and a detailed histological analysis did not reveal polycystic ovaries in these animals [40]. Interestingly, these transgenic NGF mice were found to be susceptible to challenge with gonadotropins (FSH and LH). After treatment with gonadotropins, the mice presented with a detectable ovarian phenotype that included the formation of massive follicular cysts [40] suggesting that endogenous steroid hormones participate in NGF-mediated ovarian dysfunction. More research needs to be done to determine whether the abnormal ovarian NGF signaling results in metabolic changes, and to elucidate what the downstream target of the NGF signaling pathway may be in relation to the development of polycystic ovaries.

Another factor implicated in human PCOS is the glycoprotein PAI-1. Several studies have shown that women with PCOS have increased levels of PAI-1 and increased PAI-1 activity [41-44]. It has also been shown that the PAI-1 polymorphism is significantly associated with the risk of developing PCOS [45]. Both pathological and

histological studies have been performed in mice overexpressing PAI-1 [35] and these mice have been found to have polycystic ovaries and increased testosterone levels that are comparable to what are seen in human PCOS. Thus, the transgenic PAI-1 mouse model could be used for future experimental investigations into the many gaps in the understanding of the interactions between reproductive and metabolic processes in human PCOS.

Concluding remarks

PCOS is a complicated endocrine disorder whose pathophysiology is the result of the interactions, combinations, and contributions of various genetic and environmental factors. Because of the heterogeneous nature of PCOS [3], it is worth noting that the majority of PCOS-like animal models rely upon external chemical treatments to be able to focus on particular aspects of the disease's clinical pathology. As outlined above, transgenic and knockout mouse models do not replicate the full spectrum of human PCOS, but they do provide opportunities to gain deeper insight into the development of PCOS. Polycystic ovaries are the morphological ovarian phenotype in human PCOS [3, 6], and there is evidence for a primary ovarian defect being the root cause of human PCOS. The use of different transgenic and knockout mouse models with their own unique ovarian phenotype(s) may help to identify and quantify changes in reproductive and endocrine networks in these animals that may lead to important clinical insights into the development of PCOS in women.

Acknowledgement

The work was supported by the Swedish Medical Research Council (Grant 5859), Jane and Dan Olsson's Foundation, the Hjalmar Svensson Foundation, Anna Cederberg's Foundation, Åke Wiberg's Foundation, Wilhelm-Martina Lundgren's Foundation, the Wennergren Foundation, and the Royal Society of Arts and Sciences in Gothenburg.

Disclosure statement

The authors have declared that there is no conflict of interest.

Address Correspondence to: Dr. Ruijin Shao, Department of Physiology/Endocrinology, Institute

of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden. Phone: +46-31 7863408; Fax: +46-31 7863512; E-mail: ruijin.shao@fysiologi.gu.se

References

- [1] Ehrmann DA. Polycystic ovary syndrome. *N Engl J Med* 2005; 352: 1223-1236.
- [2] March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ and Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. *Hum Reprod* 2010; 25: 544-551.
- [3] Norman RJ, Dewailly D, Legro RS and Hickey TE. Polycystic ovary syndrome. *Lancet* 2007; 370: 685-697.
- [4] Jansen E, Laven JS, Dommerholt HB, Polman J, van Rijt C, van den Hurk C, Westland J, Mosselman S and Fauser BC. Abnormal gene expression profiles in human ovaries from polycystic ovary syndrome patients. *Mol Endocrinol* 2004; 18: 3050-3063.
- [5] Wood JR, Nelson VL, Ho C, Jansen E, Wang CY, Urbaneck M, McAllister JM, Mosselman S and Strauss JF 3rd. The molecular phenotype of polycystic ovary syndrome (PCOS) theca cells and new candidate PCOS genes defined by microarray analysis. *J Biol Chem* 2003; 278: 26380-26390.
- [6] Franks S, Stark J and Hardy K. Follicle dynamics and anovulation in polycystic ovary syndrome. *Hum Reprod Update* 2008; 14: 367-378.
- [7] Hall JE, Taylor AE, Hayes FJ and Crowley WF Jr. Insights into hypothalamic-pituitary dysfunction in polycystic ovary syndrome. *J Endocrinol Invest* 1998; 21: 602-611.
- [8] Jakimiuk AJ, Weitsman SR, Navab A and Maggoffin DA. Luteinizing hormone receptor, steroidogenesis acute regulatory protein, and steroidogenic enzyme messenger ribonucleic acids are overexpressed in thecal and granulosa cells from polycystic ovaries. *J Clin Endocrinol Metab* 2001; 86: 1318-1323.
- [9] Dunaif A and Thomas A. Current concepts in the polycystic ovary syndrome. *Annu Rev Med* 2001; 52: 401-419.
- [10] Nemade RV, Carrette O, Larsen WJ and Markoff E. Involvement of nitric oxide and the ovarian blood follicle barrier in murine follicular cyst development. *Fertil Steril* 2002; 78: 1301-1308.
- [11] Matzuk MM, DeMayo FJ, Hadsell LA and Kumar TR. Overexpression of human chorionic gonadotropin causes multiple reproductive defects in transgenic mice. *Biol Reprod* 2003; 69: 338-346.

Polycystic ovary-like mouse models

- [12] Risma KA, Clay CM, Nett TM, Wagner T, Yun J and Nilson JH. Targeted overexpression of luteinizing hormone in transgenic mice leads to infertility, polycystic ovaries, and ovarian tumors. *Proc Natl Acad Sci U S A* 1995; 92: 1322-1326.
- [13] Risma KA, Hirshfield AN and Nilson JH. Elevated luteinizing hormone in prepubertal transgenic mice causes hyperandrogenemia, precocious puberty, and substantial ovarian pathology. *Endocrinology* 1997; 138: 3540-3547.
- [14] Meehan TP, Harmon BG, Overcast ME, Yu KK, Camper SA, Puett D and Narayan P. Gonadal defects and hormonal alterations in transgenic mice expressing a single chain human chorionic gonadotropin-lutropin receptor complex. *J Mol Endocrinol* 2005; 34: 489-503.
- [15] Rulli SB, Kuorelahti A, Karaer O, Pelliniemi LJ, Poutanen M and Huhtaniemi I. Reproductive disturbances, pituitary lactotrope adenomas, and mammary gland tumors in transgenic female mice producing high levels of human chorionic gonadotropin. *Endocrinology* 2002; 143: 4084-4095.
- [16] Kumar TR, Wang Y, Lu N and Matzuk MM. Follicle stimulating hormone is required for ovarian follicle maturation but not male fertility. *Nat Genet* 1997; 15: 201-204.
- [17] Kumar TR, Palapattu G, Wang P, Woodruff TK, Boime I, Byrne MC and Matzuk MM. Transgenic models to study gonadotropin function: the role of follicle-stimulating hormone in gonadal growth and tumorigenesis. *Mol Endocrinol* 1999; 13: 851-865.
- [18] Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE and Witchel SF. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. *Fertil Steril* 2009; 91: 456-488.
- [19] Adams JM, Taylor AE, Crowley WF Jr and Hall JE. Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome. *J Clin Endocrinol Metab* 2004; 89: 4343-4350.
- [20] Brawer JR, Naftolin F, Martin J and Sonnenschein C. Effects of a single injection of estradiol valerate on the hypothalamic arcuate nucleus and on reproductive function in the female rat. *Endocrinology* 1978; 103: 501-512.
- [21] Brawer JR, Munoz M and Farookhi R. Development of the polycystic ovarian condition (PCO) in the estradiol valerate-treated rat. *Biol Reprod* 1986; 35: 647-655.
- [22] Lee MT, Anderson E and Lee GY. Changes in ovarian morphology and serum hormones in the rat after treatment with dehydroepiandrosterone. *Anat Rec* 1991; 231: 185-192.
- [23] Manneras L, Cajander S, Holmang A, Seleskovic Z, Lystig T, Lonn M and Stener-Victorin E. A New Rat Model Exhibiting Both Ovarian and Metabolic Characteristics of Polycystic Ovary Syndrome. *Endocrinology* 2007; 148: 3781-3791.
- [24] Kaipia A and Hsueh AJ. Regulation of ovarian follicle atresia. *Annu Rev Physiol* 1997; 59: 349-363.
- [25] Leung PC, Goldenberg SR and Armstrong DT. Changes with age in aromatization of testosterone in immature female rats. *Biol Reprod* 1978; 19: 1036-1039.
- [26] Leung PC and Armstrong DT. Estrogen treatment of immature rats inhibits ovarian androgen production in vitro. *Endocrinology* 1979; 104: 1411-1417.
- [27] Magoffin DA and Erickson GF. Mechanism by which 17 beta-estradiol inhibits ovarian androgen production in the rat. *Endocrinology* 1981; 108: 962-969.
- [28] Britt KL, Drummond AE, Cox VA, Dyson M, Wreford NG, Jones ME, Simpson ER and Findlay JK. An age-related ovarian phenotype in mice with targeted disruption of the Cyp 19 (aromatase) gene. *Endocrinology* 2000; 141: 2614-2623.
- [29] Ito Y, Fisher CR, Conte FA, Grumbach MM and Simpson ER. Molecular basis of aromatase deficiency in an adult female with sexual infantilism and polycystic ovaries. *Proc Natl Acad Sci U S A* 1993; 90: 11673-11677.
- [30] Couse JF, Bunch DO, Lindzey J, Schomberg DW and Korach KS. Prevention of the polycystic ovarian phenotype and characterization of ovulatory capacity in the estrogen receptor-alpha knockout mouse. *Endocrinology* 1999; 140: 5855-5865.
- [31] Lee S, Kang DW, Hudgins-Spivey S, Krust A, Lee EY, Koo Y, Cheon Y, Gye MC, Chambon P and Ko C. Theca-specific Esr1 knockout mice lose fertility prematurely. *Endocrinology* 2009 Aug; 150: 3855-62.
- [32] Dupont S, Krust A, Gansmuller A, Dierich A, Chambon P and Mark M. Effect of single and compound knockouts of estrogen receptors alpha (ERalpha) and beta (ERbeta) on mouse reproductive phenotypes. *Development* 2000; 127: 4277-4291.
- [33] Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS and Smithies O. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. *Proc Natl Acad Sci U S A* 1993; 90: 11162-11166.
- [34] Schomberg DW, Couse JF, Mukherjee A, Lubahn DB, Sar M, Mayo KE and Korach KS.

Polycystic ovary-like mouse models

- Targeted disruption of the estrogen receptor-alpha gene in female mice: characterization of ovarian responses and phenotype in the adult. *Endocrinology* 1999; 140: 2733-2744.
- [35] Devin JK, Johnson JE, Eren M, Gleaves LA, Bradham WS, Bloodworth JR Jr and Vaughan DE. Transgenic overexpression of plasminogen activator inhibitor-1 promotes the development of polycystic ovarian changes in female mice. *J Mol Endocrinol* 2007; 39: 9-16.
- [36] Legro RS, Spielman R, Urbanek M, Driscoll D, Strauss JF 3rd and Dunaif A. Phenotype and genotype in polycystic ovary syndrome. *Recent Prog Horm Res* 1998; 53: 217-256.
- [37] Heine PA, Taylor JA, Iwamoto GA, Lubahn DB and Cooke PS. Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. *Proc Natl Acad Sci U S A* 2000; 97: 12729-12734.
- [38] Dissen GA, Lara HE, Leyton V, Paredes A, Hill DF, Costa ME, Martinez-Serrano A and Ojeda SR. Intraovarian excess of nerve growth factor increases androgen secretion and disrupts estrous cyclicity in the rat. *Endocrinology* 2000; 141: 1073-1082.
- [39] Lara HE, Dissen GA, Leyton V, Paredes A, Fuenzalida H, Fiedler JL and Ojeda SR. An increased intraovarian synthesis of nerve growth factor and its low affinity receptor is a principal component of steroid-induced polycystic ovary in the rat. *Endocrinology* 2000; 141: 1059-1072.
- [40] Dissen GA, Garcia-Rudaz C, Paredes A, Mayer C, Mayerhofer A and Ojeda SR. Excessive ovarian production of nerve growth factor facilitates development of cystic ovarian morphology in mice and is a feature of polycystic ovarian syndrome in humans. *Endocrinology* 2009; 150: 2906-2914.
- [41] Sampson M, Kong C, Patel A, Unwin R and Jacobs HS. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. *Clin Endocrinol (Oxf)* 1996; 45: 623-629.
- [42] Atiomo WU, Bates SA, Condon JE, Shaw S, West JH and Prentice AG. The plasminogen activator system in women with polycystic ovary syndrome. *Fertil Steril* 1998; 69: 236-241.
- [43] Tarkun I, Canturk Z, Arslan BC, Turemen E and Tarkun P. The plasminogen activator system in young and lean women with polycystic ovary syndrome. *Endocr J* 2004; 51: 467-472.
- [44] Orio F Jr, Palomba S, Cascella T, Tauchmanova L, Nardo LG, Di Biase S, Labella D, Russo T, Savastano S, Tolino A, Zullo F, Colao A and Lombardi G. Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome? *Reprod Biomed Online* 2004; 9: 505-510.
- [45] Bagos PG. Plasminogen activator inhibitor-1 4G/5G and 5,10-methylene-tetrahydrofolate reductase C677T polymorphisms in polycystic ovary syndrome. *Mol Hum Reprod* 2009; 15: 19-26.